

1                   **Proteomics Investigation of Diverse Serological Patterns in COVID-19**

2

3   Xiao Liang<sup>1,2,3,4</sup>, Rui Sun<sup>2,3,4</sup>, Jing Wang<sup>5</sup>, Kai Zhou<sup>5</sup>, Jun Li<sup>5</sup>, Shiyong Chen<sup>5</sup>, Mengge Lyu<sup>2,3,4</sup>,  
4   Sainan Li<sup>2,3,4</sup>, Zhangzhi Xue<sup>2,3,4</sup>, Yingqiu Shi<sup>2,3,4</sup>, Yuting Xie<sup>2,3,4</sup>, Qiushi Zhang<sup>6</sup>, Xiao Yi<sup>6</sup>, Juan  
5   Pan<sup>5</sup>, Donglian Wang<sup>5</sup>, Jiaqin Xu<sup>5</sup>, Hongguo Zhu<sup>5</sup>, Guangjun Zhu<sup>5</sup>, Jiansheng Zhu<sup>5</sup>, Yi Zhu<sup>2,3,4,6</sup>,  
6   Yufen Zheng<sup>5\*</sup>, Bo Shen<sup>5\*</sup>, Tiannan Guo<sup>1,2,3,4\*</sup>

7

8   <sup>1</sup> *Fudan University, Shanghai, China;*

9   <sup>2</sup> *Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake*  
10 *University, Hangzhou, Zhejiang, China;*

11 <sup>3</sup> *Center for Infectious Disease Research, Westlake Laboratory of Life Sciences and Biomedicine,*  
12 *Hangzhou, Zhejiang, China;*

13 <sup>4</sup> *Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou, Zhejiang,*  
14 *China;*

15 <sup>5</sup> *Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Linhai,*  
16 *Zhejiang, China;*

17 <sup>6</sup> *Westlake Omics (Hangzhou) Biotechnology Co., Ltd., Hangzhou, Zhejiang, China.*

18 \* Corresponding authors

19

20 Correspondence: Y.Z ([zhengyf@enzemed.com](mailto:zhengyf@enzemed.com)), B.S ([shenb@enzemed.com](mailto:shenb@enzemed.com)), and T.G  
21 ([guotiannan@westlake.edu.cn](mailto:guotiannan@westlake.edu.cn))

22

23 Running title: Proteomes behind diverse COVID-19 serology

24 Keywords: COVID-19; serology; proteomics; inflammation; cellular immunity.

## 25 **Abbreviations**

26 ADE, antibody-dependent enhancement; ARDS, acute respiratory distress syndrome; C1,  
27 complement 1; CLIA, chemiluminescence immunoassay; COVID-19, Coronavirus Disease 2019;  
28 CV, coefficient of variation; DDA, data-dependent acquisition; DEP, differentially expressed  
29 protein; EHR, electronic hospital record; HDL-C, high-density lipoprotein cholesterol; IQR,  
30 interquartile range; LDL-C, low-density lipoprotein cholesterol; LOESS, locally weighted  
31 scatterplot smoothing NAb, neutralizing antibody; nonVac, non-vaccinated; PCA, principal  
32 component analysis; R1, one-year revisit; R2, two-year revisit; RBD, receptor binding domain;  
33 RLU, relative luminescence unit; RT-PCR, reverse-transcriptase polymerase-chain-reaction; TC,  
34 total cholesterol; TEAB, triethylammonium bicarbonate; TG, triglyceride; TMT, tandem mass tag;  
35 Vac, vaccinated.

## 37 **Abstract**

38 Serum antibodies IgM and IgG are elevated during COVID-19 to defend against viral attack.  
39 Atypical results such as negative and abnormally high antibody expression were frequently  
40 observed whereas the underlying molecular mechanisms are elusive. In our cohort of 144 COVID-  
41 19 patients, 3.5% were both IgM and IgG negative whereas 29.2% remained only IgM negative.  
42 The remaining patients exhibited positive IgM and IgG expression, with 9.3% of them exhibiting  
43 over 20-fold higher titers of IgM than the others at their plateau. IgG titers in all of them were  
44 significantly boosted after vaccination in the second year. To investigate the underlying molecular  
45 mechanisms, we classed the patients into four groups with diverse serological patterns and  
46 analyzed their two-year clinical indicators. Additionally, we collected 111 serum samples for  
47 TMTpro-based longitudinal proteomic profiling and characterized 1494 proteins in total. We  
48 found that the continuously negative IgM and IgG expression during COVID-19 were associated  
49 with mild inflammatory reactions and high T cell responses. Low levels of serum IgD, inferior  
50 complement 1 activation of complement cascades, and insufficient cellular immune responses  
51 might collectively lead to compensatory serological responses, causing overexpression of IgM.  
52 Serum CD163 was positively correlated with antibody titers during seroconversion. This study

53 suggests that patients with negative serology still developed cellular immunity for viral defense,  
54 and that high titers of IgM might not be favorable to COVID-19 recovery.

55

## 56 **Introduction**

57 COVID-19 remains a threat to global health. The production of serum antibodies in the  
58 human body is a major defensive mechanism to neutralize SARS-CoV-2. Within them, IgM is  
59 initiated during the acute phase for early defense whereas IgG is secreted afterwards with a higher  
60 affinity for SARS-CoV-2 (1). Typically, COVID-19 patients underwent seroconversion (from  
61 negative to positive) of IgM and IgG within 20 days (2). The IgM and IgG expression kept  
62 elevating before reaching the plateau, with IgG plateau titers higher and longer-lasting than IgM  
63 plateau titers (3). The timespans of seroreversion (from positive to negative) were around 3-6  
64 months since disease onset for IgM (4, 5) whereas hardly observed for IgG in one year (6). After  
65 vaccination, convalescent COVID-19 patients exhibited higher titers of IgM and IgG compared to  
66 healthy individuals (7).

67 Several atypical serological patterns were documented in the literature. 3.2% to 6.9% of the  
68 COVID-19 patients remained low expression or seronegative for both IgM and IgG throughout the  
69 disease stage (1, 2). It has also been reported that less than 10% of the patients exhibited 10- to 20-  
70 fold higher antibody titers than the average values when reaching the plateau (1, 8). These  
71 unexpected serological patterns indicate heterogeneous host responses during COVID-19, with  
72 unclear molecular mechanisms.

73 This study was designed to investigate the diverse expression patterns of IgM and IgG from a  
74 single-center cohort across two years of monitoring, and to explore the molecular evidence  
75 associated with atypical antibody expression via longitudinal proteomic profiling.

76

## 77 **Experimental procedures**

### 78 **Ethics and data governance approval**

79 This study has been approved by the Ethical/Institutional Review Board of Westlake  
80 University and Taizhou Hospital (approval notice: K20210218). The studies in this work abide by

81 the Declaration of Helsinki principles. Since archived specimens were used, informed consent  
82 from the patients was waived by the boards. A flowchart of the study design is illustrated in Figure  
83 1D.

#### 84 **Patient information**

85 We included 144 COVID-19 patients who were admitted to Taizhou Public Health Medical  
86 Center, Taizhou Hospital from January 17, 2020 to April 2, 2020. Within them, seventy-three  
87 patients participated in the one-year follow-up between day 363-397 (IQR, 10) since disease onset  
88 and fifty-eight patients participated in the two-year follow-up between day 728-763 (IQR, 7) since  
89 disease onset.

90 Information about demographics, epidemiological history, clinical symptoms, laboratory  
91 data, and hospitalization was collected through an electronic medical record system. All enrolled  
92 patients were confirmed to be infected with SARS-CoV-2 by use of real-time reverse-transcriptase  
93 polymerase-chain-reaction (RT-PCR) assay on the viral RNA extracted from nasopharyngeal or  
94 sputum specimens, and the classification of their disease severity were based on Diagnostic and  
95 Treatment Protocol for COVID-19 (Trial Version 5) issued by National Health Commission of the  
96 People's Republic of China (9), unless otherwise mentioned. The onset date was defined as the  
97 day when any symptoms were noticed by the patients.

#### 98 **Removal of identifying information**

99 All information that would allow the patient/study participant or their family, friends or  
100 neighbors to identify them (e.g., age, past medical history, etc.) has been removed. Patient IDs  
101 from hospital records have been replaced with identifiers that cannot reveal the identity of the  
102 study subjects (e.g., R001, R002, etc.). The correspondence between identifiers and patient IDs  
103 was not known to anyone outside the research group.

#### 104 **Laboratory characteristic tests**

105 Nasopharyngeal or sputum specimens were collected to extract SARS-CoV-2 RNA, using a  
106 nucleic acid extractor (EX3600, Shanghai Zhijiang) and a virus nucleic acid extraction kit  
107 (P20200201, Shanghai Zhijiang). For nucleic acid detection, fluorescence quantitative PCR (ABI  
108 7500, Thermo) coupled to a SARS- CoV-2 nucleic acid detection kit (P20200203, Shanghai

109 Zhijiang) were used, which use a one-step RT-PCR combined with Taqman technology to detect  
110 RdRp, E, and N genes. “Positive” was concluded when the test for RdRp was positive (threshold  
111 cycle < 43) and one of the tests for E or N was positive (threshold cycle <43), or when two  
112 sequential tests of RdRp were positive whereas the tests for E and N were negative. Other  
113 laboratory characteristic tests were conducted according to the manufacturer’s protocols.

#### 114 **Antibody analyses**

115 The IgM and IgG antibodies against SARS-CoV-2 in serum samples were measured with the  
116 chemiluminescence immunoassay (CLIA) kits (iFLASH3000, Shenzhen YHLO). CLIAs were  
117 conducted based on two-step indirect immunization according to the manufacturer’s instructions.  
118 The recombinant nucleocapsid protein (N) and spike protein (S) antigens of SARS-CoV-2 were  
119 enveloped on magnetic beads, and an acridine ester labeled mouse anti-human IgM/IgG antibody  
120 was used as the detection antibody. The IgM/IgG antibody concentrations were positively  
121 correlated with the Relative Luminescence Unit (RLU). The cut-off to determine positivity was set  
122 at 10 AU/mL.

123 The neutralizing antibodies (NAbs) against SARS-CoV-2 in serum samples were measured  
124 using CLIA kits (Caris 200, Wantai). CLIAs for neutralizing antibody detection were based on  
125 competition immunization according to the manufacturer’s instructions. The neutralizing antibody  
126 in the sample and the biotinylated SARS-CoV-2 specific antibody compete with acridine ester  
127 labeled S protein. Next, streptavidin-coated magnetic particles were added. Through the  
128 interaction of biotin and streptavidin, a complex consisting of the magnetic particles coated by  
129 streptavidin, biotinylated SARS-CoV-2 specific antibody, and acridine ester S protein was formed.  
130 After washing and removing the substances that do not bind to the magnetic particles. The  
131 neutralizing antibody concentration in the sample was inversely proportional to the instrumentally  
132 detected RLU. The cut-off value to determine NAb positivity was set at 0.1  $\mu\text{g/mL}$ .

#### 133 **Patient classification based on antibody titers**

134 The classification of COVID-19 patients was based on the maximum expression levels of  
135 IgM and IgG when reaching the plateau. The cut-off value, as determined by the detection kit, was  
136 10 AU/mL. A total of 47 patients had IgM titers below the cut-off value ( $\text{IgM}^-$ ), and three had IgG

137 titers below the cut-off value (IgG<sup>-</sup>). They were classified as seronegative for IgM and IgG,  
138 respectively.

139 Two patients had IgG titers above but close to the cut-off value. Specifically, the IgG plateau  
140 was reached on the second and the 18<sup>th</sup> day after the symptoms' onset for patients R055 (16.11  
141 AU/mL) and R101 (13.80 AU/mL), respectively. These were the “outliers” of the patients with  
142 IgG plateau titers above the cut-off value, accordingly to Tukey's test (Figure S2A). Clinicians  
143 classified them as seronegative for IgG (IgG<sup>-</sup>). Similarly, nine patients with very high IgM  
144 expression were the “outliers” in the patients with IgM plateau titers above the cut-off value,  
145 accordingly to Tukey's test. Clinicians classed them as patients with abnormally high IgM  
146 expression (IgM<sup>++</sup>).

#### 147 **Proteomic analysis**

148 Serum samples were heated at 56 °C for over 60 min for inactivation. The sample preparation  
149 procedures were conducted as described previously (10) with several modifications: 10 µL serum  
150 from each specimen of the sample cohort was extracted and loaded onto High Select Top14  
151 Abundant Protein Depletion Mini Spin Columns (Thermo Scientific) for high abundance protein  
152 depletion. Eluates were concentrated using Pierce™ Protein Concentrators PES, 3K MWCO  
153 (Thermo Scientific), and denatured with 50 µL lysis buffer (6 M urea and 2 M thiourea in 0.1 M  
154 triethylammonium bicarbonate, TEAB) at 31 °C for 30 min. The extracts were reduced with 10  
155 mM tris (2-carboxyethyl) phosphine (Damas-beta) at 31°C for 40 min and alkylated with 40 mM  
156 iodoacetamide (Sigma) at 25°C for 40 min in darkness. The samples were diluted with 0.1 M  
157 TEAB buffer till the final concentration of urea was below 1.6 M, and trypsinized (Hualishi  
158 Technology) in double-step with an enzyme-to-substrate ratio of 1:20 at 31°C, for 60 min and 120  
159 min, respectively. Trypsinization was stopped by adding trifluoroacetic acid (Damas-beta) till the  
160 final concentration of 1%, and digests were desalted with SOLAµ (Thermo Fisher Scientific),  
161 following the manufacturer's instructions. Clean peptides were labeled with TMTpro 16plex label  
162 reagent sets (Thermo Scientific) according to the labeling set (Figure S2). A pooled sample was  
163 generated for labeling efficiency tests to ensure an incorporation ratio of over 95%. Afterward,  
164 samples in the batch were combined and fractionated in previously described settings (10). 60

165 fractions were derived and consolidated into 26 combined fractions. The fractions were dried and  
166 re-dissolved in 30  $\mu$ L 2% ACN/0.1% formic acid. For nanoLC-MS/MS analysis, an EASY-nLC™  
167 1200 system (Thermo Fisher Scientific) coupled with Q Exactive HF-X hybrid Quadrupole-  
168 Orbitrap (Thermo Fisher Scientific) was applied, and data-dependent acquisition (DDA) mode  
169 was used throughout the analysis. The parameters were as previously described (10), except a 60  
170 min LC gradient was applied for each acquisition. The resultant data were analyzed with Proteome  
171 Discoverer (Version 2.4.1.15). Protein database was a *Homo sapiens fasta* file downloaded from  
172 UniprotKB on April 10, 2020 and other parameter settings were as previously described (10).

### 173 **Statistical analysis**

174 For clinical data (demographic information and clinical indicators), p values were calculated  
175 by two-sided Wilcoxon rank-sum tests. For proteomics data, p values were calculated by one-way  
176 analysis of variance (ANOVA) in the comparisons of divergent antibody expression and by two-  
177 sided Student's t-test in other analyses. Benjamini & Hochberg correction was applied for p-value  
178 adjustment and labeled as *adjusted p*. Paired analyses were applied in comparing DEPs and in the  
179 comparisons of clinical indicators from organ dysfunction. Signs: \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p$   
180  $< 0.005$ ; \*\*\*\*,  $p < 0.001$ . Spearman correlation coefficients were calculated for the correlation of  
181 clinical data and proteomic data. LOESS (locally weighted scatterplot smoothing) model was  
182 applied for fitting analysis. Unsupervised hierarchical clustering was applied to display the DEPs  
183 from dysregulated seroconversion.

184 Categorical variables were described as frequency and percentage, and continuous variables  
185 were shown as mean and standard deviation or median and interquartile range (IQR) values as  
186 appropriate. To compare the continuous variables for data from different patient groups, an  
187 independent t-test was used when the data were normally distributed; otherwise, the Kruskal-  
188 Wallis H test was conducted. The categorical variables were compared using the  $\chi^2$  test and  
189 Fisher's exact test as appropriate. Statistical analyses were performed with R software (version  
190 3.6.0).

### 191 **Pathway analysis**

192 Metascape (11), String (12), and Ingenuity Pathway Analysis were applied for pathway  
193 enrichment in this study.

194

## 195 **Results**

### 196 **Negative and exceptionally high IgM and IgG expression in COVID-19**

197 We procured a cohort of 144 COVID-19 patients and used chemiluminescence  
198 immunoassays (CLIAs) to assess their expression levels of IgM and IgG (Methods). 790, 72, and  
199 58 CLIA tests were conducted during the first 10 weeks since disease onset (weeks 1-10), the one-  
200 year revisit (R1), and the two-year revisit (R2), respectively. 84.5% of the revisited patients  
201 received vaccination between R1 and R2 (Table S1). Based on their plateau titers during weeks 1-  
202 10, the antibodies' expression patterns were classified as follows: - for negative results or very low  
203 expression, + for positive results, and ++ for exceptionally high expression (Methods).

204 Accordingly, patients were classified into four groups:  $\text{IgG}^- \text{IgM}^-$  ( $\text{G}^- \text{M}^-$ ,  $N = 5$ ),  $\text{IgG}^+ \text{IgM}^-$   
205 ( $\text{G}^+ \text{M}^-$ ,  $N = 42$ ),  $\text{IgG}^+ \text{IgM}^+$  ( $\text{G}^+ \text{M}^+$ ,  $N = 88$ ), and  $\text{IgG}^+ \text{IgM}^{++}$  ( $\text{G}^+ \text{M}^{++}$ ,  $N = 9$ ) (Figure S1A and  
206 S1B).

207 We firstly assessed the IgM expression dynamics in the four groups.  $\text{G}^+ \text{M}^+$  and  $\text{G}^+ \text{M}^{++}$   
208 patients underwent IgM seroconversion between weeks 1-2 (Figure 1A). However, the IgM titers  
209 in the  $\text{G}^+ \text{M}^{++}$  group were significantly higher since week 2 and were over 20-fold in expression  
210 when reaching the plateau at week 4, compared to that in the  $\text{G}^+ \text{M}^+$  group. The IgM titers in the  
211  $\text{G}^+ \text{M}^{++}$  group remained over ten-fold higher than the  $\text{G}^+ \text{M}^+$  group at weeks 7-10. Comparatively,  
212 none of the patients in the  $\text{G}^+ \text{M}^-$  or the  $\text{G}^- \text{M}^-$  group underwent IgM seroconversion during  
213 weeks 1-10. The overall IgM titers of the four groups had a significant decrease from weeks 1-10  
214 to R1, which were further decreased at R2. Only 13.9% ( $N = 10$ ) and 5.2% ( $N = 3$ ) of the revisited  
215 patients were IgM seropositive at R1 and R2, respectively. The statistical differences in IgM titers  
216 between the  $\text{G}^+ \text{M}^-$  and the  $\text{G}^+ \text{M}^+$  groups persisted at R1 and R2, suggesting a long-term effect of  
217 COVID-19.

218 As for the IgG expression dynamics, all the groups except the  $\text{G}^- \text{M}^-$  group underwent  
219 seroconversion at weeks 1-2 and reached the plateau at week 3 (Figure 1B). Their IgG titers



220 remained at plateau levels during weeks 3-6. Thereafter, the IgG titers exhibited a mild decrease in  
221 the G<sup>+</sup>M<sup>++</sup> group at weeks 7-10. By contrast, IgG seroconversion was hardly observed in the G<sup>-</sup>  
222 M<sup>-</sup> group, and most of the IgG titers in the G<sup>-</sup>M<sup>-</sup> group were below the positivity cut-off value  
223 during weeks 1-10. The overall IgG titers in the four groups exhibited a significant decrease from  
224 weeks 1-10 to R1. Statistical differences in IgG titers between G<sup>+</sup>M<sup>-</sup> and G<sup>+</sup>M<sup>+</sup> patients were also  
225 observed at R1. The IgG expression of all of the groups was significantly enhanced from R1 to  
226 R2, which might be attributed to vaccination (Table S1).

227

### 228 **Vaccination boosts IgG expression in COVID-19**

229 To evaluate the effect of vaccination on IgG expression, we classed the convalescent patients  
230 at R2 into non-vaccinated (nonVac, N = 9) and vaccinated (Vac, N = 49) groups and compared  
231 their IgG titers (Figure 1C). The Vac group exhibited significantly elevated IgG titers from R1 to  
232 R2. All of the Vac patients were seropositive at R2, including one G<sup>-</sup>M<sup>-</sup> patient R009.  
233 Comparatively, IgG titers in the nonVac group were equivalent between R1 and R2. These  
234 observations showed that vaccination can significantly boost IgG expression for COVID-19  
235 convalescents. We also conducted 255 CLIA tests of neutralizing antibody (NAb) expression in 85  
236 patients from the cohort throughout weeks 1-10 and R1 (Table S1). The NAb titers were relatively  
237 higher in the G<sup>+</sup>M<sup>+</sup> and G<sup>+</sup>M<sup>++</sup> groups (Figure S1C) compared to others, suggestive of their  
238 stronger neutralizing abilities. NAb and IgG were positively correlated in all of the groups except  
239 for G<sup>-</sup>M<sup>-</sup> (Figure S1C), whereas NAb and IgM were not correlated (Figure S1D).

240 Our observation showed that COVID-19 patients underwent highly diverse antibody  
241 expression, especially IgM, after viral infection. IgM turned negative while IgG persisted with a  
242 significant decrease one year after COVID-19. IgG titers were significantly boosted after  
243 vaccination.

244

### 245 **COVID-19 severity and on-admission inflammation were positively correlated with antibody 246 expression**

247 We assessed the electronic hospital records (EHRs) of the enrolled patients (Figure 2 and

248 Table S2). None of the  $G^-M^-$  patients were severe cases, whereas 34.1% of the  $G^+M^+$  patients  
249 and 33.3% of the  $G^+M^{++}$  patients had severe symptoms, respectively (Figure 2A). Supportively,  
250 the  $G^+M^+$  and  $G^+M^{++}$  groups had significantly higher amounts of infected lung lobes and received  
251 more drug therapies, including immunoglobulin and methylprednisolone, compared to other  
252 groups (Table S2).

253 To investigate the difference in the basic physiological status among the four groups, we  
254 compared their clinical indicators on admission (Figure 2B). Notably, risk factors such as SAA,  
255 CRP and inflammation factors such as IL-6, IL-10, and IFN- $\gamma$ , were positively correlated with  
256 IgM and IgG expression, suggesting that patients with higher antibody titers also had stronger  
257 inflammatory responses. Coagulation factor fibrinogen remained at a normal range in the  $G^-M^-$   
258 group but overexpressed in some patients from the other groups, suggesting a tendency of  
259 coagulopathy in these patients. The lymphocyte amounts were negatively correlated with antibody  
260 titers and below the lower limit of normal ranges in most of the  $G^+M^{++}$  patients, suggesting that  
261 their baseline immunological status was inferior to the other patients. A series of nutritional  
262 factors such as albumin and pre-albumin, which have been reported as potential indicators for  
263 adverse outcomes in COVID-19 (13, 14), was negatively correlated with antibody expression  
264 titers.

265 To sum up, the severity and inflammation status of COVID-19 patients on admission were  
266 positively correlated with their antibody expression titers.

267

### 268 **Enhanced cellular immune responses are associated with negative IgM and IgG expression**

269 We monitored the two-year temporal changes of serum clinical indicators in our cohort  
270 (Figure 2C). In the  $G^+M^{++}$  group, the expression of CD3, CD4, and CD8, three T lymphocyte  
271 markers, was below the lower limit of the reference ranges during weeks 1-3 and was significantly  
272 lower than the other groups during weeks 1-10. CD19, a B lymphocyte marker, was lower in the  
273  $G^+M^{++}$  group than the other groups throughout weeks 1-10 and fell below the lower limit of the  
274 reference range since week 4. Comparatively, these CD markers were highly expressed in the  $G^-$   
275  $M^-$  group until week 5. The inter-group differences of these CD markers decreased after week 7.

276 These observations suggested that the G<sup>-</sup>M<sup>-</sup> patients exhibited stronger cellular immune  
277 responses compared to the other groups. Neutrophil counts during weeks 1-4 increased in the  
278 G<sup>+</sup>M<sup>++</sup> group whereas remained equivalent in the other groups. Notably, starting from week 6,  
279 neutrophil counts in the G<sup>+</sup>M<sup>++</sup> and G<sup>+</sup>M<sup>+</sup> groups increased beyond the upper limit of the  
280 reference range. The decrease of B and T lymphocytes and the increase of neutrophils during  
281 hospitalization have been previously observed in severe (15) and deceased (16) COVID-19  
282 patients.

283 The temporal expression of several blood lipids and lipoproteins was different between the G  
284 <sup>-</sup>M<sup>-</sup> group and the others (Figure 2C). Triglyceride (TG) increased during weeks 1-3 followed by  
285 a gradual decrease in the four groups, but only the G<sup>-</sup>M<sup>-</sup> group went back to reference ranges by  
286 week 5. The G<sup>-</sup>M<sup>-</sup> group also exhibited relatively higher expression of total cholesterol (TC),  
287 lipoprotein(a), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein  
288 cholesterol (HDL-C) during weeks 1-10. The combination of low HDL-C and high TG, termed  
289 atherogenic dyslipidemia, was considered a risk factor for severe COVID-19 (17). These  
290 observations suggest different levels of systematic dyslipidemia during COVID-19, which were  
291 the mildest in the G<sup>-</sup>M<sup>-</sup> group.

292 Taken together, patients who remained both IgM and IgG seronegative during disease had  
293 enhanced cellular immune responses whereas less perturbation of lipid metabolism, compared to  
294 the other patients.

295

### 296 **Serum proteomic investigation of four serological groups**

297 To understand the differences in host responses behind the diverse antibody expression, we  
298 collected 111 serum samples from 16 representative COVID-19 patients (Figure S2A) to profile  
299 their longitudinal proteomic signatures during weeks 1-10 (Figure 3A). A total of 1494 proteins  
300 were characterized using TMTpro 16plex technology (Figure S2B and Table S3). The median  
301 value of the protein coefficient of variation (CV) for the pooled samples is 0.189 (Figure S2C),  
302 indicating high quality of our data.

303 To explore the proteomic differences among the four groups, ANOVA was used to assess  
304 differentially expressed proteins (DEPs) (adjusted p value < 0.05) at each week. 77 DEPs in total  
305 were identified, 61.0% (n = 47) of which were from weeks 1-2 (Figure S2D). Only one of these 47  
306 proteins was overlapped with the DEPs from weeks 4-10, suggesting a distinct difference in the  
307 host responses during and after seroconversion. Accordingly, we found that the  $G^{-}M^{-}$  and  $G^{+}M^{++}$   
308 groups could be stratified by the DEPs during weeks 1-2 but not weeks 4-10 via principal  
309 component analysis (PCA, Figure 3B).

310 We next analyzed the key functions of the DEPs. The three most enriched pathways  
311 throughout weeks 1-10 are humoral immune responses, glycosaminoglycan binding, and  
312 carbohydrate binding (Figure 3C). Within them, humoral immune responses include multiple  
313 established risk factors of COVID-19, such as complement and fibrinogen factors (10, 18). The  
314 enrichment of Glycosaminoglycan binding might be attributed to either cytokine recognition or  
315 SARS-CoV-2 host entry (19). We then clustered the DEPs at the initial (weeks 1-2) and late  
316 (weeks 7-10) stages of COVID-19 via String (12). Complement system and prothrombin  
317 activation were the main enriched functions during weeks 1-2 (Figure 3D). Notably, the  
318 expression of C1QB and C1QC, subunits of complement 1 (C1), were significantly lower in the  $G^{-}M^{-}$   
319 group compared to the  $G^{+}M^{-}$  and  $G^{+}M^{+}$  groups and further decreased in the  $G^{+}M^{++}$  group  
320 (Figure 3E). Comparatively, a list of downstream proteins of complement cascade, including  
321 C4BPA, C7, CFI, and CFH, were significantly upregulated in the  $G^{+}M^{++}$  group (Figure 3D). This  
322 observation suggested that complement system was strongly activated in the  $G^{+}M^{++}$  group but not  
323 via the classical C1-mediated pathway. P0DOX3, an IgD heavy chain residue, was negatively  
324 correlated with IgM expression in the four groups (Figure 3E), suggesting that IgD may  
325 compensate for the lack of IgM in the  $G^{-}M^{-}$  and  $G^{+}M^{-}$  groups (20). At weeks 7-10, leukocyte  
326 extravasation signaling was enriched (Figure 3F). Within them, VNN1, a proposed HDL regulator  
327 (21), was significantly upregulated in the  $G^{+}M^{++}$  group (Figure 3G). FCGR3A was also  
328 overexpressed in the  $G^{+}M^{++}$  group, which might enhance the production of pro-inflammatory  
329 cytokines and the activities of cytotoxic effector cells (22).

330 In summary, the proteomic differences in the four groups were the most prominent during  
331 weeks 1-2, which were associated with complement cascades. The main host response differences  
332 during the late stage of COVID-19 relate to the leukocyte activities.

333

#### 334 **Correlation between serum proteomes and clinical indicators**

335 Beyond the functional analyses, we explored the correlation between the DEPs and the  
336 antibody titers during weeks 1-4 since disease onset. Five and four DEPs were significantly  
337 correlated with IgM and IgG expression titers (absolute value of Spearman correlation coefficient  
338 is over 0.5), respectively (Figure 4A). Within them, TIMP1, ICAM1, CD163, NOTCH2, and  
339 HLD-DRB1 are associated with inflammatory response, corroborating the important role of  
340 inflammation in serology. CD163, a marker for monocytic macrophages (23), is the most  
341 correlated protein with IgG among these regulators. As exemplified in Figure 4B, the expression  
342 of serum CD163 was positively correlated with antibody titers and was significantly higher than  
343 the other groups in the G<sup>+</sup>M<sup>+</sup> group throughout weeks 1-4, suggestive of their more activated  
344 macrophage polarization during COVID-19 (24).

345 We also assessed the correlation between clinical indicators and DEPs during weeks 1-10  
346 (Figure 4C). HDL-C was significantly correlated with MERTK (Figure 4D), a transmembrane  
347 kinase that contributes to the B lymphocyte activation (25). TG was positively correlated with  
348 serum CD34 (Figure 4E), a human hematopoietic stem cell marker that also has a role in  
349 facilitating inflammatory cell trafficking. These evidences further suggested lipid involvement in  
350 the immunological activities during COVID-19.

351

#### 352 **A putative working model for diverse serology in COVID-19**

353 Based on our data, we propose a putative working model regarding the diverse COVID-19  
354 serology (Figure 4F). Complement cascade is initiated upon disease onset, mediating the secretion  
355 of cytokines such as IL-6 and IL-10. This process could trigger macrophage polarization, as  
356 exemplified by the upregulation of CD163, which would further modulate local inflammation. The  
357 subsequently activated neutrophils and T lymphocytes could initiate B cell differentiation, leading

358 to the activation of humoral immune responses to secret antibodies. These processes might be  
359 barely activated in the  $G^{-}M^{-}$  group due to *a priori* cellular immune responses that efficiently  
360 confront the invasion of SARS-CoV-2 upon disease onset. On the contrary, the cellular immunity  
361 might not be sufficient in the  $G^{+}M^{++}$  group for viral defense. Meanwhile, the activation of  
362 complement 1 might be disturbed in the  $G^{+}M^{++}$  group. The high expression of inflammatory  
363 factors and rapidly ascending IgM titers might be a complementary process to defend against viral  
364 attacks.

365

## 366 **Discussion**

367 In this study, we extracted two-year EHRs and applied TMTpro 16plex-based longitudinal  
368 proteomics to investigate the host responses of patients with diverse serology in COVID-19. We  
369 found that patients with negative IgM and IgG expression still developed strong T cell immunity  
370 for viral defense, and that the overexpression of IgM was associated with perturbed complement  
371 cascades and insufficient cellular immune responses.

372 Multiple studies have reported the association between antibody expression and COVID-19  
373 severity. For example, Long *et al.* observed higher titers of IgM and IgG in severe patients than in  
374 mild patients since seroconversion (1). Garcia-Beltran *et al.* found that severe COVID-19 patients  
375 that required intubation or were passed away had the highest levels of IgG and IgA antibodies  
376 compared to others (26). However, none of them have studied the mechanisms underlying the  
377 differentiated antibody expression. Our manifestation that antibody expression was associated  
378 with on-admission inflammatory responses supports a previous speculation that severe disease  
379 might be caused by hyper-inflammation, which induces antibody overproduction (26). Conversely,  
380 high antibody titers might be involved in the antibody-dependent enhancement (ADE) of viral  
381 entry, which further induces the expression of inflammatory factors (27).

382 Our observation that a list of CD molecules (CD3, CD4, CD8, and CD19) were highly  
383 expressed in the  $G^{-}M^{-}$  patients whereas decreased in the  $G^{+}M^{++}$  patients during COVID-19  
384 suggested their differentially regulated lymphocytes to confront viral attacks. The low expression  
385 of T and B lymphocyte markers, namely lymphopenia, has been established as a severity hallmark

386 in previous studies (15, 28), further supporting our data. Notably, intra-group differences of these  
387 molecules were not as significant after week 5, which might result from medical treatment (29).  
388 Therefore, the evaluation of lymphopenia on COVID-19 severity is recommended within one  
389 month since disease onset. Comparatively, CD163 as shown in our serum proteomics data was  
390 continuously upregulated during seroconversion in the G<sup>+</sup>M<sup>++</sup> group. The high expression of  
391 CD163 has also been detected in the autopsy samples of six organs in the deceased COVID-19  
392 patients (30), the peripheral blood mononuclear cells during COVID-19, and the THP-1 cell line  
393 after 48 hours of SARS-CoV-2 infection (24). A recent study reported that an overexpression of  
394 pulmonary CD163 might lead to idiopathic pulmonary fibrosis in COVID-19 (31). These  
395 observations collectively suggest that overly activated macrophage functions might not be  
396 favorable to COVID-19 recovery.

397 Although lipid metabolism dysregulation is typical in COVID-19 (10), our data showed that  
398 seronegative patients had the mildest symptoms of dyslipidemia compared to others. This might  
399 be attributed to their relatively milder inflammation, which mediates cytokine secretion that alters  
400 lipid homeostasis (32). We also found clues that HDL-C and TG might be associated with  
401 leukocyte activation during COVID-19. Mechanistic studies are needed in the future to explore  
402 their causality.

403 Our observation that SARS-CoV-2-specific IgG declined significantly one year after  
404 COVID-19 was in line with previous reports (33), suggesting a transition into immune memories.  
405 This also underlined the necessity of vaccinating recovered populations, which could significantly  
406 enhance IgG titers two years after COVID-19, according to our data. Notably, 85.7% (N = 42) of  
407 the vaccinated patients in our cohort received at least two doses of inactivated vaccines as of R2.  
408 Previous studies have shown that one to two doses of adenoviral vector or mRNA vaccines, were  
409 also viable to boost IgG and NAb titers in the recovered patients (7, 34). A longer-term serological  
410 monitoring of the same cohort is expected to understand the long-term humoral immunity in the  
411 vaccinated population with previous SARS-CoV-2 infection.

412 Our study has several limitations. Firstly, the single-center study with a relatively small  
413 patient cohort was possibly subject to demographic and experimental biases. Also, the sampling

414 time points failed to cover the seroreversion stages for IgG. Furthermore, as the major purpose is  
415 to profile host responses associated with diverse serology patterns, we didn't validate specific  
416 markers in this study.

417

### 418 **Data availability**

419 Patient information and serology data are available in the supplementary material. The  
420 proteomic raw data are deposited in ProteomeXchange Consortium  
421 (<https://www.iprox.cn/page/PSV023.html?url=1660551727880pH06>, password: VcQ7).

422

### 423 **Acknowledgments**

424 This work was supported by grants from National Key R&D Program of China  
425 (2021YFA1301602, 2020YFE0202200), National Natural Science Foundation of China  
426 (81972492, 21904107, 82072333), Zhejiang Provincial Natural Science Foundation for  
427 Distinguished Young Scholars (LR19C050001), Hangzhou Agriculture and Society Advancement  
428 Program (20190101A04), Medical Science and Technology Project of Zhejiang Province  
429 (2021KY394), Westlake Education Foundation, and Scientific Research Foundation of Taizhou  
430 Enze Medical Center (Group) (21EZZX01). We thank Westlake University Supercomputer Center  
431 for assistance in data storage and computation.

432

### 433 **Author Contributions**

434 Y.Z., B.S., and T.G. designed the project, Y.Z., J.W., K.Z., D.W., and G.Z. collected the samples,  
435 X.L., J.W., K.Z., J.L, S.C., M.L., J.P., J.X., H.Z., and G.Z. organized the sample information, X.L.,  
436 S.L., and X.Y. prepared the samples, X.L., M.L., Y.S., Y.X., and Q.Z. performed the data analysis,  
437 X.L., Y.X., and Q.Z. designed the figures, X.L. and R.S. wrote the manuscript, Y.Z., B.S., Y.Z.,  
438 and T.G. supervised the project.

439

### 440 **Competing Interests statement**

441 Q.Z. and X.Y. are employees of Westlake Omics Inc. Y.Z. and T.G. are shareholders of Westlake



442 Omics Inc. The remaining authors declare no competing interests.

443

444 **Supplementary data**

445 This article contains supplemental material Table S1-S3 and Figure S1-S2.

446

447

## 448 **References**

- 449 1. Long, Q. X., Liu, B. Z., Deng, H. J., Wu, G. C., Deng, K., Chen, Y. K., Liao, P., Qiu, J. F., Lin, Y.,  
450 Cai, X. F., Wang, D. Q., Hu, Y., Ren, J. H., Tang, N., Xu, Y. Y., Yu, L. H., Mo, Z., Gong, F., Zhang, X.  
451 L., Tian, W. G., Hu, L., Zhang, X. X., Xiang, J. L., Du, H. X., Liu, H. W., Lang, C. H., Luo, X. H., Wu, S.  
452 B., Cui, X. P., Zhou, Z., Zhu, M. M., Wang, J., Xue, C. J., Li, X. F., Wang, L., Li, Z. J., Wang, K., Niu, C.  
453 C., Yang, Q. J., Tang, X. J., Zhang, Y., Liu, X. M., Li, J. J., Zhang, D. C., Zhang, F., Liu, P., Yuan, J., Li,  
454 Q., Hu, J. L., Chen, J., and Huang, A. L. (2020) Antibody responses to SARS-CoV-2 in patients  
455 with COVID-19. *Nat Med* 26, 845-848
- 456 2. Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., Qian, S.,  
457 Hong, C., Wang, F., Liu, Y., Wang, Z., He, Q., Li, Z., He, B., Zhang, T., Fu, Y., Ge, S., Liu, L., Zhang, J.,  
458 Xia, N., and Zhang, Z. (2020) Antibody Responses to SARS-CoV-2 in Patients With Novel  
459 Coronavirus Disease 2019. *Clin Infect Dis* 71, 2027-2034
- 460 3. Jin, Y., Wang, M., Zuo, Z., Fan, C., Ye, F., Cai, Z., Wang, Y., Cui, H., Pan, K., and Xu, A. (2020)  
461 Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019.  
462 *International Journal of Infectious Diseases* 94, 49-52
- 463 4. Iyer, A. S., Jones, F. K., Nodoushani, A., Kelly, M., Becker, M., Slater, D., Mills, R., Teng, E.,  
464 Kamruzzaman, M., Garcia-Beltran, W. F., Astudillo, M., Yang, D., Miller, T. E., Oliver, E., Fischinger,  
465 S., Atyeo, C., Iafate, A. J., Calderwood, S. B., Lauer, S. A., Yu, J., Li, Z., Feldman, J., Hauser, B. M.,  
466 Caradonna, T. M., Branda, J. A., Turbett, S. E., LaRocque, R. C., Mellon, G., Barouch, D. H.,  
467 Schmidt, A. G., Azman, A. S., Alter, G., Ryan, E. T., Harris, J. B., and Charles, R. C. (2020)  
468 Persistence and decay of human antibody responses to the receptor binding domain of SARS-  
469 CoV-2 spike protein in COVID-19 patients. *Sci Immunol* 5, eabe0367
- 470 5. den Hartog, G., Vos, E. R. A., van den Hoogen, L. L., van Boven, M., Schepp, R. M., Smits, G.,  
471 van Vliet, J., Woudstra, L., Wijmenga-Monsuur, A. J., van Hagen, C. C. E., Sanders, E. A. M., de  
472 Melker, H. E., van der Klis, F. R. M., and van Binnendijk, R. S. (2021) Persistence of Antibodies to  
473 Severe Acute Respiratory Syndrome Coronavirus 2 in Relation to Symptoms in a Nationwide  
474 Prospective Study. *Clin Infect Dis* 73, 2155-2162
- 475 6. Masiá, M., Fernández-González, M., Telenti, G., Agulló, V., García, J. A., Padilla, S., García-

Proteomes behind diverse COVID-19 serology

---

- 476 Abellán, J., Galiana, A., Gonzalo-Jiménez, N., and Gutiérrez, F. (2021) Durable antibody response  
477 one year after hospitalization for COVID-19: A longitudinal cohort study. *J Autoimmun* 123,  
478 102703-102703
- 479 7. Ali, H., Alahmad, B., Al-Shammari, A. A., Alterki, A., Hammad, M., Cherian, P., Alkhairi, I.,  
480 Sindhu, S., Thanaraj, T. A., Mohammad, A., Alghanim, G., Deverajan, S., Ahmad, R., El-Shazly, S.,  
481 Dashti, A. A., Shehab, M., Al-Sabah, S., Alkandari, A., Abubaker, J., Abu-Farha, M., and Al-Mulla,  
482 F. (2021) Previous COVID-19 Infection and Antibody Levels After Vaccination. *Frontiers in public*  
483 *health* 9, 778243-778243
- 484 8. Geyer, P. E., Arend, F. M., Doll, S., Louiset, M.-L., Virreira Winter, S., Müller-Reif, J. B., Torun,  
485 F. M., Weigand, M., Eichhorn, P., Bruegel, M., Strauss, M. T., Holdt, L. M., Mann, M., and Teupser,  
486 D. (2021) High-resolution serum proteome trajectories in COVID-19 reveal patient-specific  
487 seroconversion. *EMBO Mol Med* 13, e14167-e14167
- 488 9. Suhre, K., McCarthy, M. I., and Schwenk, J. M. (2020) Genetics meets proteomics:  
489 perspectives for large population-based studies. *Nat Rev Genet*
- 490 10. Shen, B., Yi, X., Sun, Y., Bi, X., Du, J., Zhang, C., Quan, S., Zhang, F., Sun, R., Qian, L., Ge, W.,  
491 Liu, W., Liang, S., Chen, H., Zhang, Y., Li, J., Xu, J., He, Z., Chen, B., Wang, J., Yan, H., Zheng, Y.,  
492 Wang, D., Zhu, J., Kong, Z., Kang, Z., Liang, X., Ding, X., Ruan, G., Xiang, N., Cai, X., Gao, H., Li, L.,  
493 Li, S., Xiao, Q., Lu, T., Zhu, Y., Liu, H., Chen, H., and Guo, T. (2020) Proteomic and Metabolomic  
494 Characterization of COVID-19 Patient Sera. *Cell* 182, 59-72.e15
- 495 11. Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A. H., Tanaseichuk, O., Benner, C.,  
496 and Chanda, S. K. (2019) Metascape provides a biologist-oriented resource for the analysis of  
497 systems-level datasets. *Nat Commun* 10, 1523
- 498 12. Szklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M.,  
499 Doncheva, N. T., Morris, J. H., Bork, P., Jensen, L. J., and Mering, C. V. (2019) STRING v11:  
500 protein-protein association networks with increased coverage, supporting functional discovery in  
501 genome-wide experimental datasets. *Nucleic Acids Res* 47, D607-d613
- 502 13. Aziz, M., Fatima, R., Lee-Smith, W., and Assaly, R. (2020) The association of low serum  
503 albumin level with severe COVID-19: a systematic review and meta-analysis. *Crit Care* 24, 255

Proteomes behind diverse COVID-19 serology

---

- 504 14. Luo, Y., Xue, Y., Mao, L., Yuan, X., Lin, Q., Tang, G., Song, H., Wang, F., and Sun, Z. (2020)  
505 Prealbumin as a Predictor of Prognosis in Patients With Coronavirus Disease 2019. *Front Med*  
506 *(Lausanne)* 7, 374
- 507 15. Akbari, H., Tabrizi, R., Lankarani, K. B., Aria, H., Vakili, S., Asadian, F., Noroozi, S., Keshavarz,  
508 P., and Faramarz, S. (2020) The role of cytokine profile and lymphocyte subsets in the severity of  
509 coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. *Life Sci* 258,  
510 118167
- 511 16. Zhao, Y., Nie, H. X., Hu, K., Wu, X. J., Zhang, Y. T., Wang, M. M., Wang, T., Zheng, Z. S., Li, X.  
512 C., and Zeng, S. L. (2020) Abnormal immunity of non-survivors with COVID-19: predictors for  
513 mortality. *Infect Dis Poverty* 9, 108
- 514 17. Masana, L., Correig, E., Ibarretxe, D., Anoro, E., Arroyo, J. A., Jericó, C., Guerrero, C., Miret,  
515 M., Näf, S., Pardo, A., Perea, V., Pérez-Bernalte, R., Plana, N., Ramírez-Montesinos, R., Royuela,  
516 M., Soler, C., Urquizu-Padilla, M., Zamora, A., and Pedro-Botet, J. (2021) Low HDL and high  
517 triglycerides predict COVID-19 severity. *Sci Rep* 11, 7217
- 518 18. D'Alessandro, A., Thomas, T., Dzieciatkowska, M., Hill, R. C., Francis, R. O., Hudson, K. E.,  
519 Zimring, J. C., Hod, E. A., Spitalnik, S. L., and Hansen, K. C. (2020) Serum Proteomics in COVID-19  
520 Patients: Altered Coagulation and Complement Status as a Function of IL-6 Level. *Journal of*  
521 *proteome research* 19, 4417-4427
- 522 19. Schneider, W. M., Luna, J. M., Hoffmann, H. H., Sánchez-Rivera, F. J., Leal, A. A., Ashbrook, A.  
523 W., Le Pen, J., Ricardo-Lax, I., Michailidis, E., Peace, A., Stenzel, A. F., Lowe, S. W., MacDonald, M.  
524 R., Rice, C. M., and Poirier, J. T. (2021) Genome-Scale Identification of SARS-CoV-2 and Pan-  
525 coronavirus Host Factor Networks. *Cell* 184, 120-132.e114
- 526 20. Lutz, C., Ledermann, B., Kosco-Vilbois, M. H., Ochsenbein, A. F., Zinkernagel, R. M., Köhler,  
527 G., and Brombacher, F. (1998) IgD can largely substitute for loss of IgM function in B cells. *Nature*  
528 393, 797-801
- 529 21. Holleboom, A. G., Vergeer, M., Hovingh, G. K., Kastelein, J. J., and Kuivenhoven, J. A. (2008)  
530 The value of HDL genetics. *Current opinion in lipidology* 19, 385-394
- 531 22. Chakraborty, S., Gonzalez, J., Edwards, K., Mallajosyula, V., Buzzanco, A. S., Sherwood, R.,

Proteomes behind diverse COVID-19 serology

---

- 532 Buffone, C., Kathale, N., Providenza, S., Xie, M. M., Andrews, J. R., Blish, C. A., Singh, U., Dugan, H.,  
533 Wilson, P. C., Pham, T. D., Boyd, S. D., Nadeau, K. C., Pinsky, B. A., Zhang, S., Memoli, M. J.,  
534 Taubenberger, J. K., Morales, T., Schapiro, J. M., Tan, G. S., Jagannathan, P., and Wang, T. T.  
535 (2021) Proinflammatory IgG Fc structures in patients with severe COVID-19. *Nature immunology*  
536 22, 67-73
- 537 23. Etzerodt, A., and Moestrup, S. K. (2013) CD163 and inflammation: biological, diagnostic, and  
538 therapeutic aspects. *Antioxid Redox Signal* 18, 2352-2363
- 539 24. Boumaza, A., Gay, L., Mezouar, S., Bestion, E., Diallo, A. B., Michel, M., Desnues, B., Raoult,  
540 D., La Scola, B., Halfon, P., Vitte, J., Olive, D., and Mege, J. L. (2021) Monocytes and Macrophages,  
541 Targets of Severe Acute Respiratory Syndrome Coronavirus 2: The Clue for Coronavirus Disease  
542 2019 Immunoparalysis. *J Infect Dis* 224, 395-406
- 543 25. Shao, W. H., Zhen, Y., Finkelman, F. D., and Cohen, P. L. (2014) The MERTK receptor tyrosine  
544 kinase promotes T-B interaction stimulated by IgD B-cell receptor cross-linking. *J Autoimmun*  
545 53, 78-84
- 546 26. Garcia-Beltran, W. F., Lam, E. C., Astudillo, M. G., Yang, D., Miller, T. E., Feldman, J., Hauser,  
547 B. M., Caradonna, T. M., Clayton, K. L., Nitido, A. D., Murali, M. R., Alter, G., Charles, R. C., Dighe,  
548 A., Branda, J. A., Lennerz, J. K., Lingwood, D., Schmidt, A. G., lafrate, A. J., and Balazs, A. B. (2021)  
549 COVID-19-neutralizing antibodies predict disease severity and survival. *Cell* 184, 476-488.e411
- 550 27. Wen, J., Cheng, Y., Ling, R., Dai, Y., Huang, B., Huang, W., Zhang, S., and Jiang, Y. (2020)  
551 Antibody-dependent enhancement of coronavirus. *Int J Infect Dis* 100, 483-489
- 552 28. Liu, K., Yang, T., Peng, X. F., Lv, S. M., Ye, X. L., Zhao, T. S., Li, J. C., Shao, Z. J., Lu, Q. B., Li, J.  
553 Y., and Liu, W. (2021) A systematic meta-analysis of immune signatures in patients with COVID-  
554 19. *Rev Med Virol* 31, e2195
- 555 29. He, R., Lu, Z., Zhang, L., Fan, T., Xiong, R., Shen, X., Feng, H., Meng, H., Lin, W., Jiang, W., and  
556 Geng, Q. (2020) The clinical course and its correlated immune status in COVID-19 pneumonia. *J*  
557 *Clin Virol* 127, 104361
- 558 30. Nie, X., Qian, L., Sun, R., Huang, B., Dong, X., Xiao, Q., Zhang, Q., Lu, T., Yue, L., Chen, S., Li,  
559 X., Sun, Y., Li, L., Xu, L., Li, Y., Yang, M., Xue, Z., Liang, S., Ding, X., Yuan, C., Peng, L., Liu, W., Yi, X.,

Proteomes behind diverse COVID-19 serology

---

- 560 Lyu, M., Xiao, G., Xu, X., Ge, W., He, J., Fan, J., Wu, J., Luo, M., Chang, X., Pan, H., Cai, X., Zhou, J.,  
561 Yu, J., Gao, H., Xie, M., Wang, S., Ruan, G., Chen, H., Su, H., Mei, H., Luo, D., Zhao, D., Xu, F., Li, Y.,  
562 Zhu, Y., Xia, J., Hu, Y., and Guo, T. (2021) Multi-organ proteomic landscape of COVID-19  
563 autopsies. *Cell* 184, 775-791.e714
- 564 31. Wendisch, D., Dietrich, O., Mari, T., von Stillfried, S., Ibarra, I. L., Mittermaier, M., Mache, C.,  
565 Chua, R. L., Knoll, R., Timm, S., Brumhard, S., Krammer, T., Zauber, H., Hiller, A. L., Pascual -  
566 Reguant, A., Mothes, R., Bülow, R. D., Schulze, J., Leipold, A. M., Djudjaj, S., Erhard, F., Geffers, R.,  
567 Pott, F., Kazmierski, J., Radke, J., Pergantis, P., Baßler, K., Conrad, C., Aschenbrenner, A. C.,  
568 Sawitzki, B., Landthaler, M., Wyler, E., Horst, D., Hippenstiel, S., Hocke, A., Heppner, F. L., Uhrig,  
569 A., Garcia, C., Machleidt, F., Herold, S., Elezkurtaj, S., Thibeault, C., Witzenrath, M., Cochain, C.,  
570 Suttorp, N., Drosten, C., Goffinet, C., Kurth, F., Schultze, J. L., Radbruch, H., Ochs, M., Eils, R.,  
571 Müller-Redetzky, H., Hauser, A. E., Luecken, M. D., Theis, F. J., Conrad, C., Wolff, T., Boor, P.,  
572 Selbach, M., Saliba, A. E., and Sander, L. E. (2021) SARS-CoV-2 infection triggers profibrotic  
573 macrophage responses and lung fibrosis. *Cell* 184, 6243-6261.e6227
- 574 32. Li, Y., Zhang, Y., Lu, R., Dai, M., Shen, M., Zhang, J., Cui, Y., Liu, B., Lin, F., Chen, L., Han, D.,  
575 Fan, Y., Zeng, Y., Li, W., Li, S., Chen, X., Li, H., and Pan, P. (2021) Lipid metabolism changes in  
576 patients with severe COVID-19. *Clin Chim Acta* 517, 66-73
- 577 33. Zhang, J., Lin, H., Ye, B., Zhao, M., Zhan, J., Dong, S., Guo, Y., Zhao, Y., Li, M., Liu, S., Zhang,  
578 H., Xiao, W., Guo, Y., Yue, C., Zhang, D., Yang, M., Zhang, J., Quan, C., Shi, W., Liu, X., Liu, P.,  
579 Jiang, Y., Wu, G., Gao, G. F., and Liu, W. J. (2021) One-year sustained cellular and humoral  
580 immunities of COVID-19 convalescents. *Clin Infect Dis*
- 581 34. Favresse, J., Gillot, C., Di Chiaro, L., Eucher, C., Elsen, M., Van Eeckhoudt, S., David, C.,  
582 Morimont, L., Dogné, J. M., and Douxfils, J. (2021) Neutralizing Antibodies in COVID-19 Patients  
583 and Vaccine Recipients after Two Doses of BNT162b2. *Viruses* 13  
584  
585

586 **Figure legends**

587 **Figure 1 Overview of antibody expression in COVID-19.** A-B) Classification and Two-year  
588 monitoring of SARS-CoV-2-specific IgM and IgG expression in COVID-19 patients. The y-axis  
589 denotes log-transformed antibody titers. The statistical significance was calculated within and  
590 across each timepoint. C) Comparison of IgG expression before and after vaccination. D) Study  
591 design for clinical and proteomic analyses of diverse serology in COVID-19.

592

593 **Figure 2 Clinical characteristics of patients with diverse serology.** A) Distributions of severe  
594 cases in the four groups. B) Expression of nine selected clinical indicators on admission. C) Two-  
595 year temporal expression of ten selected clinical indicators.

596

597 **Figure 3 Longitudinal serum proteomics of 16 characteristic patients with diverse serology.**

598 A) Temporal serum sampling for the 16 characteristic patients. B) Heatmap and functional  
599 annotation of 77 DEPs across 10 weeks of proteomic profiling. C) PCA of serum samples  
600 stratified by the DEPs at weeks 1-2 and weeks 4-10, respectively. The ellipses are shown at a  
601 confidence interval of 95%. D) Interaction network of selected DEPs at weeks 1-2. E) Relative  
602 expression of DEPs C1QB, C1QC, and IgD at weeks 1-2. F) Interaction network of selected DEPs  
603 at weeks 7-10. G) Relative expression of DEPs VNN1 and FCGR3A at weeks 7-10.

604


605 **Figure 4 Correlations of DEPs with antibody and clinical indicators expression.** A) Nine

606 DEPs that were correlated with antibody expression during weeks 1-4 (absolute values of  
607 spearman correlation  $> 0.5$ ). B) Temporal expression of CD163 during weeks 1- 4. C)

608 Correlations of clinical indicators with DEPs during weeks 1-10 (absolute values of spearman  
609 correlation  $> 0.65$ ). D-E) Scatterplots of two sets of correlations: MERTK~HDL-C and


610 CD34~TG, respectively. F) A putative working model for the host responses behind diverse  
611 COVID-19 serology.

**Figure 1**






**Figure 2**



### Figure 3



## Figure 4

